anti-ctla-4/pd-1 expressing egfr-car-t cells
Cell therapyexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jun 7, 2017 (NCT03182816)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Tumor antigensImmunity, passive
immunity, passive - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- anti-ctla-4/pd-1 expressing egfr-car-t cells
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03182816 | Phase 1/Phase 2 (Phase 2) | Jun 7, 2017 | Ningbo No. 5 Hospital, Shanghai Cell Therapy Research Institute |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ningbo No. 5 Hospital | Academic/Hospital | 1 | 0 | 1 | 2017 |
| Shanghai Cell Therapy Research Institute | Academic/Hospital | 1 | 1 | 1 | 2017 |
2 organizations
Page 1 / 1